ACR Convergence 2025 speakers reviewed new fibromyalgia insights, from the first new drug approval since 2009 to nociplastic pain concepts & cognitive behavioral therapy.
Emerging Treatments in Psoriatic Arthritis
At a scientific session of ACR Convergence 2025, Alexis Ogdie, MD, discussed new and forthcoming treatments for psoriatic arthritis.
Let’s Discuss Part 2: More Insights from the ACR Convergence 2025 Review Course
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on cutaneous manifestations of rheumatic diseases, gout, macrophage activation syndrome and vasculitis are presented here.
Gout & Cardiometabolic Co-Morbidities
ACR Convergence 2025 experts explore gout’s deep ties to MetS, insulin resistance and cardiovascular mortality, weighing new data on colchicine, febuxostat and SGLT2 inhibitors.
What’s New in Psoriatic Arthritis?
Dr. David Pisetsky curated the research presented at ACR Convergence 2025 and answers the question “What new research on psoriatic arthritis has the potential to impact patient care or future research?”
Let’s Discuss: Insights from the ACR Convergence 2025 Review Course
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.
Promising Combination Treatment for Gout
The FDA has accepted a biologics license application for nano-encapsulated sirolimus with pegylated-adricase (NASP), a combination treatment designed to reduce serum uric acid levels in patients with uncontrolled gout.
Pediatric Rheumatologist with Lupus Models Hope & Resilience for Her Patients
From educating her colleagues to sharing stories of hope & words of encouragement with her patients, pediatric rheumatology resident Adaobi Ugochukwu draws on her own experience with lupus to ensure that patients receive empathetic, compassionate care.
Study: Reducing Cardiovascular Risks Helps Lupus Patients
Long-term remission & control of CVD risk factors can reduce the risk of atherosclerosis in lupus; triple APL positivity raises the risk of CVD, study finds.
What Clinicians Should Know About Midfoot Osteoarthritis
Midfoot OA experts offer an overview of a common, but under-recognized, form of OA, & discuss quality of life impacts, treatments, clinical evaluation procedures & the critical need for further research.
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 352
- Next Page »